Pulse Biosciences (NASDAQ:PLSE) was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating in a research note issued to investors on Friday.
Shares of Pulse Biosciences (NASDAQ PLSE) traded down $0.13 on Friday, reaching $24.78. 150,888 shares of the company’s stock traded hands, compared to its average volume of 150,065. Pulse Biosciences has a 12 month low of $5.25 and a 12 month high of $39.50.
Pulse Biosciences (NASDAQ:PLSE) last posted its quarterly earnings results on Tuesday, November 7th. The company reported ($0.52) earnings per share for the quarter.
Institutional investors have recently added to or reduced their stakes in the stock. State Street Corp purchased a new position in Pulse Biosciences in the 2nd quarter valued at about $4,538,000. Vanguard Group Inc. lifted its holdings in Pulse Biosciences by 49.7% in the 2nd quarter. Vanguard Group Inc. now owns 267,810 shares of the company’s stock valued at $9,247,000 after purchasing an additional 88,902 shares in the last quarter. Northern Trust Corp lifted its holdings in Pulse Biosciences by 859.3% in the 2nd quarter. Northern Trust Corp now owns 97,554 shares of the company’s stock valued at $3,369,000 after purchasing an additional 87,385 shares in the last quarter. Wells Fargo & Company MN increased its stake in shares of Pulse Biosciences by 21,473.2% during the 2nd quarter. Wells Fargo & Company MN now owns 53,933 shares of the company’s stock valued at $1,862,000 after acquiring an additional 53,683 shares during the last quarter. Finally, Bank of New York Mellon Corp increased its stake in shares of Pulse Biosciences by 113.9% during the 3rd quarter. Bank of New York Mellon Corp now owns 55,567 shares of the company’s stock valued at $1,034,000 after acquiring an additional 29,588 shares during the last quarter. Institutional investors and hedge funds own 9.35% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This news story was originally published by Sports Perspectives and is the sole property of of Sports Perspectives. If you are accessing this news story on another site, it was stolen and republished in violation of United States and international copyright law. The original version of this news story can be read at https://sportsperspectives.com/2017/12/17/pulse-biosciences-plse-rating-increased-to-hold-at-bidaskclub.html.
About Pulse Biosciences
Pulse Biosciences, Inc, formerly Electroblate, Inc, is a development-stage medical device company using a platform technology called Nano-Pulse Electro-Signaling (NPES). NPES is a local and drug-free technology that utilizes nanosecond pulsed electric fields to induce cell signaling and the activation of cellular pathways in tissue.
Receive News & Ratings for Pulse Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulse Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.